Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth - GBI Research Reports

Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth

Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth - GBI Research Reports
Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
Published Oct 15, 2011
148 pages — Published Oct 15, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth, which provides insights into the Neurodegenerative Disease Market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the major neurodegenerative disease including Alzheimers disease, Multiple sclerosis, Parkinson disease, Diabetic neuropathy and also orphan neurodegenerative diseases such as Huntingtons disease and Amyotrophic lateral sclerosis. The report also provides information on the share of generics in Neurodegenerative Disease Markets and examines the global treatment usage patterns for neurodegenerative diseases. In addition, the geographical distribution of neurodegenerative diseases and therapeutics market across the US, the top five countries of Europe and in Japan. The report also includes insights into the neurodegenerative disease therapeutics research and development (R&D) product pipeline and explores the competitive landscape, including major players in the Neurodegenerative Disease Market. Finally, the report also includes analysis of the Mergers and Acquisitions (M&As) and licensing agreements that have taken place in the Neurodegenerative Disease Market.

Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global neurodegenerative disease market for the six indications that includes Alzheimers disease, Multiple sclerosis, Parkinsons disease, Diabetic neuropathy and orphan neurodegenerative disease such as Huntingtons disease and Amyotrophic lateral sclerosis.
- Data and analysis on the neurodegenerative disease market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the neurodegenerative disease market from 2002 to 2010, with market forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in global neurodegenerative disease market and for the market of each indication that are covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global neurodegenerative disease market including top companies benchmarking. The key companies studied in this report are Teva, Novartis, Merck, Pfizer and Boehringer Ingelheim, Bayer Schering and Biogen Idec.
- Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the neurodegenerative disease market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry

  
Source:
Document ID
GBIHC101MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents48
  List of Tables73
  List of Figures102
Neurodegenerative Disease Market to 2017 - Introduction122
  GBI Research Report Guidance131
Neurodegenerative Disease Market to 2017 - Global Market Overview147
  Introduction142
  Revenue161
    Generic Share171
  Annual Cost of Treatment181
  Treatment Usage Patterns191
    Diseased Population201
    Treatment Seeking Population201
    Diagnosis Population201
    Prescription Population201
Neurodegenerative Disease Market to 2017 - Geographical Landscape2114
  The US231
    Revenue231
    Annual Cost of Treatment241
    Treatment Usage Patterns251
      Diseased Population261
      Treatment Seeking Population261
      Diagnosis Population261
      Prescription Population261
  Top Five Countries of Europe271
    Revenue271
    Annual Cost of Treatment281
    Treatment Usage Patterns291
      Diseased Population301
      Treatment Seeking Population301
      Diagnosis Population301
      Prescription Population301
  Japan311
    Revenue311
    Annual Cost of Treatment321
    Treatment Usage Patterns331
      Diseased Population341
      Treatment Seeking Population341
      Diagnosis Population341
      Prescription Population341
Neurodegenerative Disease Market to 2017 - Therapeutic Landscape3561
    Introduction352
    Revenue372
      Revenue by Country392
      Generic Share411
    Annual Cost of Treatment421
    Treatment Usage Patterns431
      Diseased Population441
      Treatment Seeking Population441
      Diagnosis Population441
      Prescription Population441
      Geriatric Population and Increased Life Expectancy451
      Expected Launch of New Drugs Will Drive the Alzheimer s Disease Therapeutics Market in Future451
      Low Diagnosis Rate Reduces Number of Patients on AD Drug Therapy461
      Slower Drug Development Programs and Recent Drug Failures Will Hamper the Development of Promising Molecules461
  Multiple Sclerosis Market461
    Introduction462
    Revenue482
      Revenue by Country501
      Generic Share511
    Annual Cost of Treatment521
    Treatment Usage Patterns531
      Diseased Population541
      Treatment Seeking Population541
      Diagnosis Population541
      Prescription Population541
  Drivers and Restraints to Multiple Sclerosis Market551
    Drivers for Multiple Sclerosis Market551
      Launch of Several High-priced Novel Disease-modifying Therapies551
      Increased Prescription Population551
    Restraints for Multiple Sclerosis Market561
      Patient Affordability and Reimbursement Issue561
      Patent Expiry of Major Drugs Is Expected to Cause Market Decline561
  Parkinson s Disease Therapeutics Market571
    Introduction571
    Revenue572
      Revenue by Country592
      Generic Share611
    Annual Cost of Treatment621
    Treatment Usage Patterns631
      Diseased Population641
      Treatment Seeking Population641
      Diagnosis Population641
      Prescription Population641
  Drivers and Restraints to Parkinson s Disease Therapeutics Market651
    Drivers for the Parkinson s Disease Therapeutics Market651
      Rise in Geriatric Population and Increase in Life Expectancy651
    Restraints for the Parkinson s Disease Therapeutics Market651
      Lack of Definite Diagnostic Techniques Delays Treatments of PD651
      Patent Expiry in Upcoming Years Will Affect the Market Growth651
  Diabetic Neuropathy Market661
    Introduction661
    Revenue671
      Revenue by Country682
      Generic Share701
    Annual Cost of Treatment711
    Treatment Usage Pattern721
      Diseased Population731
      Treatment Seeking Population731
      Diagnosis Population731
      Prescription Population731
  Drivers and Restraints to Diabetic Neuropathy Therapeutics Market741
    Drivers for Diabetic Neuropathy Market741
      Expected Launch of New Molecules Will Drive the Diabetic Neuropathy Therapeutics Market Growth in Future741
      Increasing Diseased Population741
    Restraints for the Diabetic Neuropathy Therapeutics Market741
      Patent Expiry741
  Huntington s Disease Market751
    Introduction751
    Revenue752
      Revenue by Country772
      Generic Share791
    Annual Cost of Treatment801
    Treatment Usage Pattern811
      Diseased Population821
      Treatment Seeking Population821
      Diagnosis Population821
      Prescription Population821
  Drivers and Restraints to the Market for Huntington s Disease831
    Drivers for Huntington s disease831
      Expected Launch of Promising and High Priced Molecules Will Drive HD Market In Future831
    Restraints for Huntington s Disease841
      Low Treatment Seeking Rate841
      Absence of Curative Therapy and Affordability Issue of Medicines841
    Introduction852
    Revenue871
      Revenue by Country882
      Generic Share901
    Annual Cost of Treatment911
    Treatment Usage Patterns921
      Diseased Population931
      Treatment Seeking Population931
      Diagnosis Population931
      Prescription Population931
  Drivers and Restraints to Amyotrophic Lateral Sclerosis Market941
    Drivers for Amyotrophic Lateral Sclerosis Market941
      Expected Launch of Promising Pipeline Molecules Will Drive the Growth of ALS Market In Future941
      Rise in Geriatric Population May Increase Burden of ALS Patient In Future941
      The Rise in Awareness among the ALS Patients May Drive the ALS Market941
      High Unmet Needs and Orphan Drug Status to New Molecules Meant To Treat ALS951
    Restraints for Amyotrophic Lateral Sclerosis Market951
      Low Diagnosis Rate951
      Patent Expiry of Rilutek951
Neurodegenerative Disease Market to 2017 - Product Pipeline Analysis9625
  Introduction961
      Introduction9710
    Diabetic Neuropathy1071
      Introduction1071
    Multiple Sclerosis1081
      Introduction1084
      Introduction1125
    ALS1171
      Introduction1172
    Huntington s disease1191
      Introduction1192
Neurodegenerative Disease Market to 2017 - Competitive Landscape1218
  Market Share Analysis1211
  Teva1221
    Company Overview1221
    SWOT Analysis1221
  Biogen Idec1231
    Company Overview1231
    SWOT Analysis1231
  Merck Serono1241
    Company Overview1241
    SWOT Analysis1241
  Bayer Schering Pharma AG1251
    Company Overview1251
    SWOT Analysis1251
  Novartis1261
    Company Overview1261
    SWOT Analysis1261
  Boehringer Ingelheim1271
    Company Overview1271
    SWOT Analysis1271
  Pfizer1281
    Company Overview1281
    SWOT Analysis1281
Neurodegenerative Disease Market to 2017 - M&A Landscape12912
  M&A Deals (2009-2010)1292
    M&A Deals by Region1311
    M&A Deals by Value1321
    Deal Summary of Top 10 M&A Deals by Value1331
      Abbott Laboratories Acquires Solvay Pharmaceuticals1331
      Biovail Completes Merger with Valeant Pharmaceuticals1331
      Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion1331
      Lundbeck Acquires Ovation Pharmaceuticals1331
      Eli Lilly and Company Acquires Avid Radiopharmaceuticals1341
      Biogen Idec Acquires Panima Pharmaceuticals1341
      H. Lundbeck Acquires Life Health1341
      Endo Pharmaceuticals Completes Acquisition of Penwest Pharmaceutical1351
      UCB Acquires Remaining Stake in Schwarz Pharma1351
      Lexicon Pharmaceuticals Completes Acquisition of Symphony Icon1351
  Licensing Deals1361
    Deal Summary1371
      Cephalon Enters Into Licensing Agreement with Mesobla1371
      Synosia Therapeutics Enters Into Licensing Agreement with UCB for SYN-115 and SYN-1181371
      Genzyme Acquires Rights of Campath from Bayer HealthCare1371
      Biogen Idec Enters Into an Agreement with Acorda Therapeutics1381
      Biovail Enters Into Licensing Agreement with ACADIA Pharmaceuticals1381
      Biogen Idec Enters Into Licensing Agreement with Knopp Neurosciences for KNS-7607041381
      Merck Serono Enters Into Licensing Agreement with Apitope Technology1391
      GlaxoSmithKline Enters Into Licensing Agreement with Impax Pharmaceuticals for IPX0661391
      Santhera Pharmaceuticals Enters Into Licensing Agreement with Ipsen for Fipamezole1391
      Biovail Laboratories International Enters Into Licensing Agreement with Kyowa Hakko Kirin1391
      Addex Pharmaceuticals Extends Collaboration Agreement With Merck &Co.1401
Neurodegenerative Disease Market to 2017 - Appendix1418
  Market Definitions1411
  Abbreviations1411
  Research Methodology1426
    Coverage1421
    Secondary Research1431
    Primary Research1431
    Therapeutic Landscape1441
      Epidemiology-based Forecasting1442
      Market Size by Geography1461
    Geographical Landscape1471
    Pipeline Analysis1471
    Competitive Landscape1471
    Expert Panel Validation1471
  Contact Us1471
  Disclaimer1471
  Sources1481

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth" Oct 15, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Neurodegenerative-Disease-Market-to-2017-Patent-Expiries-of-High-Selling-Drugs-Such-as-Aricept-Namenda-Avonex-Rebif-and-Copaxone-will-Restrain-Growth-2115-283>
  
APA:
GBI Research Reports. (2011). Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth Oct 15, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Neurodegenerative-Disease-Market-to-2017-Patent-Expiries-of-High-Selling-Drugs-Such-as-Aricept-Namenda-Avonex-Rebif-and-Copaxone-will-Restrain-Growth-2115-283>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.